Literature DB >> 9264355

Impact of menstrual phase on false-negative mammograms in the Canadian National Breast Screening Study.

C J Baines1, M Vidmar, G McKeown-Eyssen, R Tibshirani.   

Abstract

BACKGROUND: The efficacy of breast carcinoma screening should be enhanced if false-negative mammography were reduced. Prospectively collected data from the Canadian National Breast Screening Study were used to examine whether menstrual cycle phase was associated with false-negative outcomes for mammographic screening.
METHODS: Of 8887 women ages 40-44 years at the onset of screening, randomized to receive annual mammography and clinical breast examination, reporting menstruation no more than 28 days prior to their screening examination, and with a valid radiologic report, 1898 had never used oral contraceptives or replacement estrogen with or without progesterone. The remainder were past (6573) and current (416) estrogen users. Similar selection criteria were applied at subsequent screens. The distribution of false-negative and false-positive mammography in relation to true-negative and true-positive mammography was examined with respect to the follicular (Days 1 to 14) and luteal (Days 15-28) menstrual phases.
RESULTS: Comparing luteal with follicular mammograms in 6989 patients who ever used estrogen, the unadjusted odds ratio (2-sided P-values) for false-negatives versus true-negatives was 2.16 (0.05) and the adjusted odds ratio was 1.47 (0.05). In 1898 never-users, parallel odds ratios for luteal false-negatives were 0.55 (1.0) and 0.74 (1.0), respectively.
CONCLUSIONS: These results suggest that menstruating women who have used hormones may have an increased risk of false-negative results for screening mammograms performed in the luteal phase of the menstrual cycle. An increased risk of false-negative mammography might adversely affect screening efficacy. The impact of menstrual phase on mammographic interpretation, especially for women who ever used hormones, requires further investigation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9264355

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Menstrual cycle-related fluctuations in breast density measured by using three-dimensional MR imaging.

Authors:  Siwa Chan; Min-Ying L Su; Fu-Ju Lei; Jia-Pei Wu; Muqing Lin; Orhan Nalcioglu; Stephen A Feig; Jeon-Hor Chen
Journal:  Radiology       Date:  2011-08-30       Impact factor: 11.105

2.  Accuracy of screening mammography varies by week of menstrual cycle.

Authors:  Diana L Miglioretti; Rod Walker; Donald L Weaver; Diana S M Buist; Stephen H Taplin; Patricia A Carney; Robert D Rosenberg; Mark B Dignan; Zhuo Tracy Zhang; Emily White
Journal:  Radiology       Date:  2010-12-03       Impact factor: 11.105

3.  Racial differences in breast cancer stage at diagnosis in the mammography era.

Authors:  Neal A Chatterjee; Yulei He; Nancy L Keating
Journal:  Am J Public Health       Date:  2012-06-14       Impact factor: 9.308

4.  Background 99mTc-methoxyisobutylisonitrile uptake of breast-specific gamma imaging in relation to background parenchymal enhancement in magnetic resonance imaging.

Authors:  Hai-Jeon Yoon; Yemi Kim; Jee Eun Lee; Bom Sahn Kim
Journal:  Eur Radiol       Date:  2014-09-13       Impact factor: 5.315

5.  Short-term hormone therapy suspension and mammography recall: a randomized trial.

Authors:  Diana S M Buist; Melissa L Anderson; Susan D Reed; Erin J Aiello Bowles; E Dawn Fitzgibbons; Juleann C Gandara; Deborah Seger; Katherine M Newton
Journal:  Ann Intern Med       Date:  2009-06-02       Impact factor: 25.391

6.  Breast cancer risk factors in relation to breast density (United States).

Authors:  Linda Titus-Ernstoff; Anna N A Tosteson; Claudia Kasales; Julia Weiss; Martha Goodrich; Elizabeth E Hatch; Patricia A Carney
Journal:  Cancer Causes Control       Date:  2006-12       Impact factor: 2.506

Review 7.  Screening for breast cancer with mammography.

Authors:  Peter C Gøtzsche; Karsten Juhl Jørgensen
Journal:  Cochrane Database Syst Rev       Date:  2013-06-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.